Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study

BACKGROUND: Oxaliplatin (OXA), a third-generation platinum derivative, has become one of the main chemotherapeutic drugs for colorectal cancer and other cancers, but reports of adverse reactions are also increasing with the extensive application of OXA. In this study, post-marketing surveillance was...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zaoqin, Huang, Rui, Zhao, Li, Wang, Ximin, Shangguan, Xiaofang, Li, Wei, Li, Min, Yin, Xianguo, Zhang, Chengliang, Liu, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567037/
https://www.ncbi.nlm.nih.gov/pubmed/34745993
http://dx.doi.org/10.3389/fonc.2021.757196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567037/
https://www.ncbi.nlm.nih.gov/pubmed/34745993
http://dx.doi.org/10.3389/fonc.2021.757196

Ejemplares similares